ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nacubactam

Also written as “RO7079901”, “co-administration of cefepime and nacubactam” and “co-administration of aztreonam and nacubactam”.

Its studies are mostly in Intraabdominal Infections · Pyelonephritis · Urinary Tract Infections · Gram-Negative Bacterial Infections · Renal Insufficiency, led by 2 companies.

Drug pageNacubactam: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 21, 20167 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only40 open or runningphase 1since Nov 21, 2016Nov 21, 2016none ahead
Meiji Seika Pharmaits history only30 open or runningphase 3since Mar 2, 2023May 7, 2014none ahead
  • Named in fosun pharma’s own pipeline as OP0595 (beta-lactamase inhibitor), phase 3, as of Sep 21, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 7, 2014First study: phase 1 study in Bacterial InfectionsNew to Meiji Seika PharmaMeiji Seika Pharma · NCT02134834 · 40 enrolled · Australia
  2. Jun 9, 2016Named nacubactamINNProposed as its International Nonproprietary Name in WHO's List 115 · before, RO7079901, OP0595
  3. Nov 21, 2016Hoffmann-La Roche’s first studies: 2 phase 1 studiesNew to Hoffmann-La RocheHoffmann-La Roche · NCT02972255, NCT02975388
  4. May 31, 2017Phase 1 study in Urinary Tract InfectionsHoffmann-La Roche · NCT03174795 · 20 enrolled · United States, Hungary, Latvia and more
  5. Jun 7, 2017Phase 1 study in Gram-Negative Bacterial InfectionsHoffmann-La Roche · NCT03182504 · 21 enrolled · United States
  6. Mar 2, 2023Phase 3 study in Complicated Urinary Tract InfectionMeiji Seika Pharma · NCT05905055 · 126 enrolled · China, Croatia, Czechia and more
  7. Apr 25, 2023Phase 3 study in Complicated Urinary Tract InfectionMeiji Seika Pharma · NCT05887908 · 614 enrolled · Bulgaria, China, Czechia and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05887908Complicated Urinary Tract Infection · Bulgaria, China, Czechia and more3CompletedMeiji Seika PharmaNov 22, 2024614
NCT05905055Complicated Urinary Tract Infection · China, Croatia, Czechia and more3CompletedMeiji Seika PharmaSep 1, 2025126
NCT03182504Gram-Negative Bacterial Infections · United States1CompletedHoffmann-La RocheAug 10, 201721
NCT03174795Urinary Tract Infections · United States, Hungary, Latvia and more1CompletedHoffmann-La RocheDec 4, 201720
NCT02975388Renal Insufficiency · United States1CompletedHoffmann-La RocheJul 6, 201729
NCT02972255Healthy Volunteers · United States1CompletedHoffmann-La RocheMar 24, 201746
NCT02134834Bacterial Infections · Australia1CompletedMeiji Seika PharmaAug 201440

How it is read

Names in the registry

  • “RO7079901”, 3 entries
  • “co-administration of cefepime and nacubactam”, 2 entries
  • “co-administration of aztreonam and nacubactam”, 2 entries
  • “nacubactam”, 1 entry
  • “OP0595”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.